Immuneel
3 known investors
Immuneel Therapeutics develops and manufactures cell-based immunotherapies, including CAR-T therapies, for cancer patients, with in-house cGMP lentiviral vector manufacturing. The company aims to make next-generation cell therapies affordable and accessible in India, with a global outlook.
Founders & leadership
KM
Kiran Mazumdar-ShawBoard Director & Co-founder
SM
Siddhartha MukherjeeBoard Director & Co-founder
AM
Amit Mookimin
Investors · 3
Competitors · 4
by search overlap
Lyell9 shared keywordsLyell is a clinical-stage biotech developing next-generation CAR T-cell product candidates intended as one-time treatments for patients with cancer, targeting both hematologic malignancies and solid tumors. The company owns and operates its own manufacturing facility to control its cell therapy supply chain.
Linkcelltx5 shared keywordsLink Cell Therapies is a biotechnology company developing logic-gate LINK CAR-T cell therapies aimed at treating solid and liquid tumors. It works in the cancer immunotherapy space and has a strategic collaboration with Johnson & Johnson.
Artielle www.artielle.com5 shared keywordsArtielle Immunotherapeutics develops DRhQ, a therapeutic platform that targets the CD74 receptor and inhibits macrophage migration inhibitory factor (MIF) to treat neuroinflammatory conditions such as progressive multiple sclerosis and advanced cancers. The company builds on research from OHSU and the VA Portland Healthcare System.
Rigel Pharmaceuticals4 shared keywordsRigel is a biopharmaceutical company that develops and markets therapies including olutasidenib, pralsetinib, and fostamatinib for conditions such as acute myeloid leukemia and chronic immune thrombocytopenia. This page invites investigator-sponsored research proposals, offering study drug and/or monetary grants for independent studies aligned with Rigel's therapeutic areas.
Companies competing with Immuneel for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Immuneel Therapeutics Raises ₹100 Crore in Series B Funding to Expand CAR-T Therapy Operations - GeneOnline Newsgeneonline.com · Aug 2026Frequently asked questions
- What does Immuneel do?
- Immuneel Therapeutics develops and manufactures cell-based immunotherapies, including CAR-T therapies, for cancer patients, with in-house cGMP lentiviral vector manufacturing. The company aims to make next-generation cell therapies affordable and accessible in India, with a global outlook.
- Who founded Immuneel?
- Immuneel was founded by Kiran Mazumdar-Shaw, Siddhartha Mukherjee.
- Who are Immuneel's investors?
- Immuneel's investors include F-Prime Capital, Vedanta Capital, Rainmatter.